Article Details

Pfizer arthritis drug Xeljanz under Health Canada scrutiny for safety risks

Retrieved on: 2021-04-06 22:18:45

Tags for this article:

Click the tags to see associated articles and topics

Pfizer arthritis drug Xeljanz under Health Canada scrutiny for safety risks. View article details on hiswai:

Excerpt

Xeljanz, which brought in worldwide sales of US$2.44 billion for Pfizer in 2020, is approved in Canada for some patients of rheumatoid arthritis, psoriatic ...

Article found on: www.ctvnews.ca

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo